© 2012


Diagnosis, Therapy, and Prognosis

  • M.A. Hayat

Part of the Pediatric Cancer book series (PECA, volume 1)

Table of contents

  1. Front Matter
    Pages i-xviii
  2. Introduction

    1. Front Matter
      Pages 1-1
    2. M.A. Hayat
      Pages 3-7
  3. Diagnosis and Biomarkers

    1. Front Matter
      Pages 9-9
    2. Hiroshi Iwakura, Takashi Akamizu
      Pages 31-38
    3. Stephen J. Smith, Brian G. Mohney
      Pages 39-45
    4. Janine Stutterheim, Godelieve A.M. Tytgat, C. Ellen van der Schoot
      Pages 47-63
    5. Marta Piqueras, Manish Mani Subramaniam, Arnaud Berthier, Samuel Navarro, Rosa Noguera
      Pages 65-75
  4. Therapy

    1. Front Matter
      Pages 77-77
    2. Mara B. Antonoff, Ashok K. Saluja
      Pages 79-90
    3. André S. Bachmann, Dirk Geerts, Giselle L. Saulnier Sholler
      Pages 91-103
    4. Rossen M. Donev, Timothy R. Hughes, B. Paul Morgan
      Pages 105-113
    5. Jamie I. Fletcher, Michelle Haber, Michelle J. Henderson, Murray D. Norris
      Pages 115-123
    6. Michela Croce, Maria Valeria Corrias, Silvano Ferrini
      Pages 125-135
    7. Erik Fredlund, Alexander Pietras, Annika Jögi, Sven Påhlman
      Pages 137-149
    8. Victoria Hoene, Christof Dame
      Pages 151-159
    9. Arturo Sala, Korn-Anong Chaiwatanasirikul
      Pages 169-176

About this book


Introduction of new technologies and their applications to neuroblastoma diagnosis, treatment, and therapy assessment are explained. Role of molecular ghenetics in diagnosis and therapy for neuroblastoma patients is detailed. Molecular detection of minimal residual neuroblastoma is described. Magnetic resonance imaging and  spectroscopy are detailed for diagnosing this solid, extracranial cancer. Targets for therapeutic intervention in neuroblastoma are identified, including targeting multidrug resistance in this cancer. Ornithine decarboxylase and polyamines are novel targets for therapeutic intervention. The effectiveness of chemotherapy with oral irinotecan and temozolomide is explained. The role of transcription factors (GATA) in neuroblastoma pregression is  also included.


Childrens tumor Diagnosis ofchildren suffering from cancer Quality of life Therapy for pediatric cancer

Editors and affiliations

  • M.A. Hayat
    • 1
  1. 1., Kean UniversityRoom 213, Library buildingUnionUSA

Bibliographic information

Industry Sectors
Health & Hospitals
Oncology & Hematology
Consumer Packaged Goods